Todorova N.Maneva K.Todorov D.2024-07-102024-07-102024-07-102024-07-102004-01-011310-281810.1080/13102818.2004.10817140SCOPUS_ID:85023994245https://rlib.uctm.edu/handle/123456789/436Condensation of the antitumor antibiotic epirubicin with oxidized chitosan provided a new conjugated antibiotic. The resultant compound was characterized by IR and UV-Vis-spectra with support the conjugate structure. The amount of epirubicin bound to the matrix was 22.5% or 315 epirubicin residues. The biological activity of epirubicin-chitosan conjugate showed an antibacterial action against Bacillus Subtilis AT 6633 on the level of the initial antibiotic. The ascetic form of lymphocytic leukemia P 388 and lymphoid leukemia L1210 (transplantation dose 106 tumor cells) in hybrid mice BDF1 was used as leukemic model. Antileukemic activity of the studied conjugate was found with a clear “dose-effect” correlation. The criterion “increase of live span” is maximally 342.1% in P338 and 371.5% in L1210 for the conjugate in comparation with maximally 179.0% in P388 and 197.2% in L1210 for the free epirubicin. The conjugate showed lower toxicity and higher therapeutic index. © 2004 Taylor and Francis Group, LLC.enArticle